Navigation Links
DermTech and Stiefel Laboratories, Inc. to Further Evaluate EGIR(TM) Technology
Date:7/15/2009

LA JOLLA, Calif., July 15 /PRNewswire/ -- DermTech, Inc., a biotechnology company developing non-invasive molecular diagnostics for the early detection of disease plus additional applications, announced that it has entered into the second part of a feasibility study using DermTech's advanced EGIR(TM) technology to help Stiefel identify specific genetic markers involved in acne. The two companies will now move forward with a proof-of-concept study to assess the use of the technology to understand the pathophysiology of acne.

Stiefel is the world's largest independent dermatology company.

"Stiefel is one of the dermatology industry's clear pioneers and is well known for innovation in the field," said George Schwartz, CEO, DermTech. "We are looking forward to together embarking on this study that will employ our advanced, genetic-based technology and believe it will appropriately be the first ever to assess the relationship between genetic changes in the skin over time and the observable clinical effects of a marketed acne treatment."

"Stiefel is committed to using the most advanced, reliable tools for the development and continued refinement of our dermatology products and candidates," said Gavin Corcoran, M.D., Chief Scientific Officer, Stiefel. "We believe that DermTech's EGIR technology, based on the most recent understanding and application of genetics to disease, offers a very strong fit with our mission to introduce breakthrough products."

About DermTech:

Headquartered in La Jolla, California, DermTech International (www.dermtech.com) is developing its proprietary EGIR(TM) (Epidermal Genetic Information Retrieval) technology for genomic-based, non-invasive disease detection, improved pharmaceutical R&D and personalized medicine to help direct appropriate treatment. The company's first product candidate in development is a non-invasive test to detect the presence of melanoma. The EGIR technology uses custom adhesive tape to easily obtain RNA from the upper layer of skin overlying a suspicious lesion. A proprietary 19-gene biomarker is then used to analyze the genetic material to differentiate potentially life-threatening melanoma from other forms of pigmented lesions. Studies to date show the test to be 100% sensitive and 88% specific. Research is also underway to use the EGIR technology to develop highly accurate, non-invasive tests for other cancers and diseases. For additional information, visit www.dermtech.com

About Stiefel Laboratories, Inc.

Stiefel Laboratories is enthusiastically committed to advancing dermatology and skin science around the world. The company's deeply-rooted dedication and drive for innovation along with its sole focus on dermatology has led Stiefel to become the largest independent dermatology company in the world. In addition to more than 30 wholly-owned subsidiaries, six manufacturing plants and a global research and development network, Stiefel's most valuable asset is its global network of nearly 3,500 driven associates.

By combining expertise, knowledge and imagination, Stiefel delivers exceptional ethical, over-the-counter and aesthetic products to its customers in more than 100 countries around the world, ultimately providing a unique Stiefel skin health experience. Stiefel also is committed to improving today's treatments and exploring tomorrow's innovations. Each year, the company invests more than $100 million USD in developing the most advanced skin health solutions. Additionally, Stiefel supplements its research and development efforts by seeking strategic partnerships and acquisitions around the world. To learn more about Stiefel, visit www.stiefel.com.

    Contacts:
    DermTech
    George Schwartz
    858.450.4222

    Jennifer Larson
    415.725.2017
    jlarson@dermtech.com


'/>"/>
SOURCE DermTech, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. DermTech and Rady Childrens Hospital-San Diego, Initiate Study to Understand Effects of Vitamin D as a Treatment for Atopic Dermatitis in Children and Young Adults
2. DermTech Names Herbert A. Fritsche, Ph.D., Chief of Clinical Chemistry at M.D. Anderson Cancer Center to Companys Scientific Advisory Board
3. DermTech Study on Melanoma Molecular Diagnostic to Be Presented at AACR
4. DermTech Is Issued U.S. Patent for the Early Detection, Staging and Monitoring of Melanoma
5. DermTech Appoints BioStatistical Pioneer, John Quackenbush, Ph.D., as a Member of the Companys Scientific Advisory Board
6. GlaxoSmithKline and Stiefel to Create New World-Leading Specialist Dermatology Business
7. Barrier Therapeutics to Merge Into Stiefel Laboratories
8. Stiefel Laboratories Appoints Two New Members to Board of Directors
9. Caraco Pharmaceutical Laboratories, Ltd. Markets Generic Casodex(R) Tablets
10. Clontech Laboratories, Inc. Releases the Xfect(TM) and Xfect(TM) Stem Transfection Reagents
11. Charleston Laboratories, Inc. Completes Exploratory Bioequivalence Study of CL-108
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:3/23/2017)... 2017 In today,s pre-market research, ... the Biotech industry: Sangamo Therapeutics Inc. (NASDAQ: SGMO), Eyegate ... SYN), and Regulus Therapeutics Inc. (NASDAQ: RGLS ... Suisse upgraded its rating on Pharmaceuticals/Biotechnology to "Overweight" from "Market Weight." Learn ... at: ...
(Date:3/22/2017)... Calif. , March 22, 2017  UBM ... proud to announce their extended partnership and the ... be headlined by the 21 st Annual ... Boston, taking place May 3-4, 2017. ... Medical Technology Association (ADVAMED) President and CEO, ...
(Date:3/22/2017)... , March 22, 2017 MarketNewsUpdates.com News ... ... conditions are being pressured as of late due to the ... pain management has a dramatic impact on patient,s quality of ... development activities for identifying new forms of opioid formulations that ...
(Date:3/22/2017)... ... March 21, 2017 , ... Okyanos Cell Therapy has announced ... of their live events series, “Stem Cell Therapy: The Next Phase in the Evolution ... 2013 Stem Cell Research and Therapy Act, Okyanos maintains a mission to ...
Breaking Biology Technology:
(Date:2/22/2017)... , Feb. 22, 2017 With ... 2021, ABI Research identifies four technologies that innovative ... to secure significant share in the changing competitive ... and passive authentication.   "Companies can ... comes to security," says Dimitrios Pavlakis , ...
(Date:2/14/2017)... , Feb. 14, 2017  Wake Forest Baptist Medical ... its new chief executive officer (CEO). Freischlag joins the ... John D. McConnell , M.D., who last year announced ... the Medical Center, after leading it since 2008.   ... scope of Wake Forest Baptist,s academic health system, which ...
(Date:2/9/2017)... LONDON , Feb. 9, 2017 The ... in-depth analysis of the biomass boiler market globally in ... sales of biomass boilers. The market for biomass boilers ... product type, end-user, application, and country/region. The market based ... agriculture & forest residues, biogas & energy crops, urban ...
Breaking Biology News(10 mins):